News

COVID-19 nasal spray vaccine offers the first line of defense against virus

15/06/2023

× CLOSE

COVID-19 nasal spray vaccine offers the first line of defense against virus

15/06/2023

Promising Results in Phase I Trial of Sodium Zirconium Cyclosilicate Offer New Treatment Option for Chinese Patients

16/12/2022

× CLOSE

Promising Results in Phase I Trial of Sodium Zirconium Cyclosilicate Offer New Treatment Option for Chinese Patients

16/12/2022

New drug offers hope of ‘functional cure’ for hepatitis B patients

06/12/2022

× CLOSE

New drug offers hope of ‘functional cure’ for hepatitis B patients

06/12/2022

Phase 1 Study Shows Synergistic Anti-tumour Efficacy of Combination of New Drug and Chemotherapy for HCC, Warranting Further Phase II/III Studies

11/04/2022

× CLOSE

Phase 1 Study Shows Synergistic Anti-tumour Efficacy of Combination of New Drug and Chemotherapy for HCC, Warranting Further Phase II/III Studies

11/04/2022

Phase 1 Study Proves Long-acting Formulation of Bupivacaine a Safe Means to Relieve Post-surgical Pain

29/09/2021

× CLOSE

Phase 1 Study Proves Long-acting Formulation of Bupivacaine a Safe Means to Relieve Post-surgical Pain

29/09/2021

Natural phytosterols prove to lower the low-density lipoprotein level and may reduce the risk of heart disease

24/05/2021

× CLOSE

Natural phytosterols prove to lower the low-density lipoprotein level and may reduce the risk of heart disease

24/05/2021

High cholesterol level is prevalent in Hong Kong. About half of the population have hypercholesterolemia. It is one of the major risk factor for cardiovascular diseases. Professor Bernard Cheung of HKU Department of Medicine and Dr. Ching-Lung Cheung of HKU Department of Pharmacy and Pharmacology conducted a 3-week clinical trial in 2015.

Successful Phase 1 Study on Novel FcRn Inhibitor Offers New Direction for Treatment of Autoimmune Disease

04/05/2021

× CLOSE

Successful Phase 1 Study on Novel FcRn Inhibitor Offers New Direction for Treatment of Autoimmune Disease

04/05/2021

Combined Use of Immunotherapy Drugs Improves Clinical Outcomes for Patients with Advanced Hepatocellular Carcinoma and Received FDA Approval as a Second-line Therapy for HCC

10/11/2020

× CLOSE

Combined Use of Immunotherapy Drugs Improves Clinical Outcomes for Patients with Advanced Hepatocellular Carcinoma and Received FDA Approval as a Second-line Therapy for HCC

10/11/2020

Immunotherapy Drug Proven Safe and Effective New Treatment for Asian HCC Patients

03/06/2020

× CLOSE

Immunotherapy Drug Proven Safe and Effective New Treatment for Asian HCC Patients

03/06/2020

Potential New Treatment for Advanced HCC Went Through Successful Phase 1 and Phase 2 Studies

31/07/2019

× CLOSE

Potential New Treatment for Advanced HCC Went Through Successful Phase 1 and Phase 2 Studies

31/07/2019